SP 500 Holds Near Flat as Consumer Stocks Rally Energy Slumps SpaceX Scrubs Starship Test Flight Aims for Friday Launch Amid Ambitious Space Goals Estate Planning Questions Handling CDs for a Parent in Hospice Care Seaport Research Highlights Data Center Power Demand as Growth Catalyst for Texas Instruments TXN ET Alpha Wealth Summit to Address Portfolio Resilience and Alpha Generation in Mumbai Chinese Drone Shipments Face Sharp Decline Amid Domestic Restrictions and US Ban SERV Q1 2026 Earnings EPS Misses Estimates Amid Revenue Uncertainty Sonoco Products SON Q1 2026 Earnings EPS Misses Estimates Despite Positive Stock Reaction ATLN Q4 2025 Earnings Significant EPS Miss Despite Stock Rally PM Q1 2026 Earnings Earnings Beat Reinforces SmokeFree Transition SmartRent Q1 2026 Earnings EPS Miss as Stock Rises 492 on Strategic Progress Aktis Oncology AKTS Q1 2026 Earnings EPS Misses Estimates as ClinicalStage Biotech Advances Pipeline Hour Loop Inc HOUR Holds Steady Near 202 as Market Watches Key Levels Assurant Inc AIZ Navigates Slight Decline While Holding Key Support Levels Security National Financial SNFCA Sees Minor Decline Holding Above Key Support at 888 Elauwit Connection ELWT Rallies 612 as Buyers Test Key Resistance at 801 Diamondback Energy FANG Slips 185 as Resistance Holds Support Levels in Focus Microsofts Trusted Technology Chief Discusses Responsible AI Development Approach TransCode Therapeutics Q4 2024 Earnings Deep Losses Reflect PreRevenue Stage Western Copper and Gold WRN Holds Near Support Amid Modest Decline FirstCash Holdings FCFS Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency ICU Medical ICUI Q1 2026 Earnings Strong EPS Beat Lifts Shares as Medical Device Demand Holds BBNX Q1 2026 Earnings NarrowerthanExpected Loss Drives DoubleDigit Stock Surge AMAL Q1 2026 Earnings EPS Misses Estimates by 174 as Stock Declines Pulmatrix Q2 2025 Earnings Loss Per Share Widens Amidst No Revenue Disclosure NVEC Q1 2026 Earnings EPS of 102 Drives Share Price Rally ANVS Q1 2026 Earnings WiderthanExpected Loss as Clinical Development Costs Persist